The advent of immunotherapy against ccRCC, such as the targeting of PD-1, PD-L1, and CTLA4, has recently been demonstrated to revolutionize the clinical treatment for ccRCC (Farkona et al., 2016). The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.